Business (Health)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Deals
US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
Cooper Completes Viatris Deal After Agreeing To Offload Brands
Cooper Consumer Health has closed its acquisition of Viatris' OTC business as it commits to divesting the rights to infant laxative medicine Bebegel and earwax removal product Otowaxol in certain markets.
Dr Reddy’s Acquiring Haleon NRTs Available Outside US In Deal Worth Up To $632M
The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Business Strategies
Sanofi In Midst Of ‘Very Competitive Process’ For Consumer Business
“The game is still totally open,” said Sanofi CFO François-Xavier Roger in response to questions about how the company intends to separate its Consumer Healthcare business. The comments came as Sanofi reported its Q2 results.
Reckitt Shakes Up Consumer Health Organization As It Narrows Group Focus
Reckitt has designated its Mead Johnson infant nutrition and home care businesses as non-core operations. The company will now reorganize to sharpen its focus on the consumer health and hygiene markets in the pursuit of sustainable, long-term growth.
People On The Move: Appointments At Perrigo, European Commission, EFSA
A round-up of the latest appointments in Europe's health and wellness industries: Perrigo makes management changes; European Commission president re-elected; EFSA appoints new members to scientific panels.
Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Sales & Earnings
Sanofi In Midst Of ‘Very Competitive Process’ For Consumer Business
“The game is still totally open,” said Sanofi CFO François-Xavier Roger in response to questions about how the company intends to separate its Consumer Healthcare business. The comments came as Sanofi reported its Q2 results.
Reckitt Shakes Up Consumer Health Organization As It Narrows Group Focus
Reckitt has designated its Mead Johnson infant nutrition and home care businesses as non-core operations. The company will now reorganize to sharpen its focus on the consumer health and hygiene markets in the pursuit of sustainable, long-term growth.
US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
Litigation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Legal Issues
Chevron’s Fall Strengthens Industry’s Hand In Disagreements With US FDA, But May Spur Delays
Firms can be more forceful in disputes with FDA now that Supreme Court has eliminated Chevron deference. Questions around whether an evidentiary standard has been met may be ripe for challenge, legal experts said, but they also caution that sponsors will face more uncertainty.
Deference No More: More Challenges Against US FDA After Supreme Court Tosses Chevron Doctrine?
The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.
Supreme Court Mifepristone Decision Sets High Bar For FDA Suits, But Risks To Agency Authority Linger
The unanimous decision that the Alliance for Hippocratic Medicine lacks standing to challenge the FDA’s relaxation of the abortion pill REMS leaves unclear whether the court would have deferred to the agency’s expertise on the merits.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.